Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

February 2, 2023

Study Completion Date

February 2, 2023

Conditions
CNS LymphomaCNS Brain CancerNon-Hodgkin's Lymphoma
Interventions
OTHER

Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide

"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00596154 - Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma | Biotech Hunter | Biotech Hunter